CY1112909T1 - Αντισωματα που κατευθυνονται εναντια στην αγγειοποιητινη (angiopoietin)-2 και χρησεις αυτων - Google Patents
Αντισωματα που κατευθυνονται εναντια στην αγγειοποιητινη (angiopoietin)-2 και χρησεις αυτωνInfo
- Publication number
- CY1112909T1 CY1112909T1 CY20111101076T CY111101076T CY1112909T1 CY 1112909 T1 CY1112909 T1 CY 1112909T1 CY 20111101076 T CY20111101076 T CY 20111101076T CY 111101076 T CY111101076 T CY 111101076T CY 1112909 T1 CY1112909 T1 CY 1112909T1
- Authority
- CY
- Cyprus
- Prior art keywords
- directed against
- antibodies directed
- ang
- antigen
- heavy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Περιγράφονται αντισώματα που κατευθύνονται ενάντια στο αντιγόνο Ang-2 και χρήσεις τέτοιων αντισωμάτων. Ειδικότερα, πλήρως ανθρώπινα μονόκλωνα αντισώματα που κατευθύνονται ενάντια στο αντιγόνο Ang-2. Αλυσίδες νουκλεοτιδίων και αλυσίδες αμινοξέος που περιλαμβάνουν μόρια ανοσογλοβουλίνης βαριάς και ελαφράς αλυσίδας, ειδικότερα αλληλουχίες που αντιστοιχούν σε συγγενείς αλληλουχίες βαριάς και ελαφράς αλυσίδας που περιέχουν τις περιοχές πλαισίου εργασίας και/ ή περιοχές καθορισμού συμπληρωματικότητας (CDRs) ειδικότερα από FR1 μέχρι FR4 ή από CDR1 μέχρι CDR3. Τα υβριδώματα ή άλλες γραμμές κυττάρων που εκφράζουν τέτοια μόρια ανοσογλοβουλίνης και μονόκλωνα αντισώματα.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63835404P | 2004-12-21 | 2004-12-21 | |
US71128905P | 2005-08-25 | 2005-08-25 | |
EP05854387A EP1838733B1 (en) | 2004-12-21 | 2005-12-19 | Antibodies directed to angiopoietin-2 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112909T1 true CY1112909T1 (el) | 2016-04-13 |
Family
ID=36405885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111101076T CY1112909T1 (el) | 2004-12-21 | 2011-11-08 | Αντισωματα που κατευθυνονται εναντια στην αγγειοποιητινη (angiopoietin)-2 και χρησεις αυτων |
Country Status (27)
Country | Link |
---|---|
US (5) | US7973140B2 (el) |
EP (3) | EP1838733B1 (el) |
JP (2) | JP4884395B2 (el) |
KR (1) | KR101017301B1 (el) |
CN (2) | CN101128483B (el) |
AR (1) | AR052065A1 (el) |
AT (1) | ATE521638T1 (el) |
AU (1) | AU2005319382B2 (el) |
BR (1) | BRPI0519596B1 (el) |
CA (1) | CA2595610C (el) |
CY (1) | CY1112909T1 (el) |
DK (1) | DK1838733T3 (el) |
ES (1) | ES2371083T3 (el) |
HK (2) | HK1109409A1 (el) |
HR (1) | HRP20110859T1 (el) |
MX (1) | MX2007007484A (el) |
NO (1) | NO20073192L (el) |
NZ (1) | NZ556029A (el) |
PL (1) | PL1838733T3 (el) |
PT (1) | PT1838733E (el) |
RS (1) | RS52036B (el) |
RU (1) | RU2394839C2 (el) |
SI (1) | SI1838733T1 (el) |
TW (1) | TW200634027A (el) |
UY (1) | UY29288A1 (el) |
WO (1) | WO2006068953A2 (el) |
ZA (1) | ZA200705695B (el) |
Families Citing this family (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
AU2001259432B2 (en) * | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
US7358353B2 (en) | 2000-08-22 | 2008-04-15 | Agensys, Inc. | Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
NZ569787A (en) * | 2005-12-15 | 2011-07-29 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer |
BRPI0710645A2 (pt) | 2006-04-07 | 2012-03-20 | The Procter & Gamble Company | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
DK2104682T3 (en) * | 2007-01-11 | 2017-01-16 | Michael Bacher | DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES |
EP2134749B1 (en) | 2007-03-22 | 2013-11-06 | The Regents of the University of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
CA2700723A1 (en) * | 2007-09-26 | 2009-04-02 | Amgen Inc. | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
WO2009059404A1 (en) * | 2007-11-05 | 2009-05-14 | University Health Network | Angiopoietin-1 and -2 biomarkers for infectious diseases that compromise endothelial integrity |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
AU2009209251B8 (en) * | 2008-01-28 | 2015-03-26 | Medimmune Limited | Stabilized Angiopoietin-2 antibodies and uses thereof |
JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
KR20110014607A (ko) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
CN102112494A (zh) | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
WO2009149189A2 (en) | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
CA2729012A1 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
BRPI0915448A2 (pt) | 2008-07-08 | 2015-11-10 | Abbott Lab | imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas |
PT3009449T (pt) | 2008-07-16 | 2018-09-28 | Inst Res Biomedicine | Anticorpos neutralizantes de citomegalovírus humano e utilização destes |
AU2013202400B2 (en) * | 2008-07-16 | 2014-10-09 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9000131B2 (en) * | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
AU2016244220B2 (en) * | 2008-12-23 | 2018-05-17 | Amgen Inc. | Human CGRP receptor binding proteins |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
EP2385763B1 (en) * | 2009-01-12 | 2018-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
JP2012521360A (ja) | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Kv1.3の選択的かつ強力なペプチド阻害剤 |
WO2010112193A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
CA2761310C (en) * | 2009-05-07 | 2017-02-28 | Charles S. Craik | Antibodies and methods of use thereof |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
EP3431501A1 (en) | 2009-06-18 | 2019-01-23 | Pfizer Inc | Anti notch-1 antibodies |
RU2519123C2 (ru) | 2009-07-06 | 2014-06-10 | Аэрпио Терапьютикс Инк. | Соединения, композиции и способы предупреждения метастазов раковых клеток |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
CN102638971B (zh) | 2009-07-08 | 2015-10-07 | 科马布有限公司 | 动物模型及治疗分子 |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US8980268B2 (en) | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
US20120189635A1 (en) | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
JP2013503607A (ja) * | 2009-09-01 | 2013-02-04 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
AU2010296018B2 (en) | 2009-09-16 | 2016-05-05 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
WO2011038139A1 (en) | 2009-09-23 | 2011-03-31 | Amgen Inc. | Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane |
RU2012119756A (ru) * | 2009-10-15 | 2013-11-20 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
MX2012003198A (es) | 2009-10-23 | 2012-06-12 | Millennium Pharm Inc | Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados. |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
KR101688522B1 (ko) * | 2009-12-15 | 2016-12-21 | 삼성전자주식회사 | 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
JO3274B1 (ar) * | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
CN101863980B (zh) * | 2009-12-31 | 2013-05-08 | 中国药科大学 | 全人源抗血管内皮细胞生长因子受体2单链抗体 |
US20110171231A1 (en) * | 2010-01-12 | 2011-07-14 | Carlos Bais | ANTI-PlGF ANTIBODIES AND METHODS USING SAME |
PT3345615T (pt) | 2010-03-01 | 2020-01-17 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
ES2739711T3 (es) | 2010-07-22 | 2020-02-03 | John W Schrader | Anticuerpo de protección cruzada contra la infección por el virus de la gripe |
EP3252072A3 (en) * | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
WO2012027570A2 (en) | 2010-08-26 | 2012-03-01 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
US9243057B2 (en) | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
EA201370076A1 (ru) | 2010-09-22 | 2013-08-30 | Амген Инк. | Иммуноглобулины-переносчики и их применение |
BR112013015122A2 (pt) * | 2010-12-15 | 2017-05-30 | Wyeth Llc | anticorpos anti-notch1 |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
KR101638224B1 (ko) | 2011-02-28 | 2016-07-08 | 에프. 호프만-라 로슈 아게 | 항원 결합 단백질 |
CN103403025B (zh) | 2011-02-28 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 单价抗原结合蛋白 |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US9512220B2 (en) | 2011-04-05 | 2016-12-06 | Neopharm Co., Ltd. | Antibodies against angiopoietins 1 and 2, and their use |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
EP3311661B1 (en) | 2011-09-19 | 2022-04-20 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP2758437B1 (en) * | 2011-09-22 | 2020-06-03 | Amgen Inc. | Cd27l antigen binding proteins |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
ES2925654T3 (es) * | 2011-09-30 | 2022-10-19 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA) |
CA2850824C (en) | 2011-10-13 | 2023-01-03 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
EP2766043A4 (en) | 2011-10-13 | 2015-06-10 | Aerpio Therapeutics Inc | METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン |
US9402898B2 (en) | 2012-01-23 | 2016-08-02 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
ES2886123T3 (es) | 2012-01-31 | 2021-12-16 | Regeneron Pharma | Anticuerpos anti-asic1 y usos de los mismos |
KR20140127854A (ko) | 2012-02-10 | 2014-11-04 | 제넨테크, 인크. | 단일-쇄 항체 및 다른 이종다량체 |
AU2013230750B2 (en) | 2012-03-08 | 2018-02-01 | Medimmune, Llc | Methods of treatment with Angiopoietin-2 antibodies |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
JP5970734B2 (ja) | 2012-03-30 | 2016-08-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ang2結合分子 |
SI2841575T1 (sl) | 2012-04-27 | 2019-11-29 | Millennium Pharm Inc | Molekule anti-GCC protitelesa in uporaba le-teh za preskušanje dovzetnosti za GCC-ciljno terapijo |
EP2867253B1 (en) | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
CN104428315B (zh) | 2012-07-13 | 2017-09-29 | 罗氏格黎卡特股份公司 | 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用 |
UA118251C2 (uk) * | 2012-08-23 | 2018-12-26 | Ейдженсіс, Інк. | Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 158p1d7 |
CN104768575B (zh) * | 2012-08-31 | 2017-09-08 | 国立大学法人大阪大学 | 含有vegf特异性表位和/或血管生成素‑2特异性表位的dna疫苗 |
US9738719B2 (en) * | 2012-08-31 | 2017-08-22 | The Scripps Research Institute | Methods and compositions related to modulators of eukaryotic cells |
KR101967345B1 (ko) | 2012-10-18 | 2019-04-09 | 삼성전자주식회사 | 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도 |
EP2914625A2 (en) | 2012-11-01 | 2015-09-09 | AbbVie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
WO2014100143A2 (en) * | 2012-12-20 | 2014-06-26 | Medimmune, Llc | Liquid antibody formulation with improved aggregation properties |
WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
WO2014120555A1 (en) | 2013-01-31 | 2014-08-07 | The Regents Of The University Of California | Antibodies specific for urokinase-type plasminogen activator and methods of use thereof |
US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
EA038918B1 (ru) | 2013-03-15 | 2021-11-09 | Зинджения, Инк. | Пептид, связывающий рецептор эпидермального фактора роста, мультиспецифические комплексы, содержащие пептид и антитела, и их применение |
AU2014228502A1 (en) | 2013-03-15 | 2015-08-20 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
EP2787006B1 (en) * | 2013-04-02 | 2018-02-28 | Miltenyi Biotec GmbH | Anti-CD8 antibody which binding is Ca2+ dependent |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
CA2912219C (en) * | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
CN103333247B (zh) * | 2013-05-30 | 2014-10-08 | 北京东方百泰生物科技有限公司 | 新型抗vegfr2的单克隆抗体及其制备与应用 |
KR102131371B1 (ko) | 2013-07-02 | 2020-07-08 | 삼성전자주식회사 | Ang-2 특이적 항체 및 그의 용도 |
EP3381940B1 (en) * | 2013-07-29 | 2022-09-07 | Samsung Electronics Co., Ltd. | Anti-ang2 antibody |
KR102146845B1 (ko) * | 2013-07-30 | 2020-08-21 | 삼성전자주식회사 | 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
KR102196450B1 (ko) * | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
CN105683365A (zh) | 2013-10-01 | 2016-06-15 | 科马布有限公司 | 动物模型及治疗分子 |
KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
CN106029694A (zh) | 2013-12-06 | 2016-10-12 | 达纳-法伯癌症研究院公司 | 治疗性肽 |
KR102206029B1 (ko) | 2014-01-27 | 2021-01-20 | 삼성전자주식회사 | Ang-2에 특이적으로 결합하는 항체 및 그의 용도 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
US10279021B2 (en) | 2014-03-14 | 2019-05-07 | Dana-Faber Cancer Institute, Inc. | Vaccine compositions and methods for restoring NKG2D pathway function against cancers |
KR101966408B1 (ko) * | 2014-04-10 | 2019-04-05 | 오비아이 파머 인코퍼레이티드 | 항체,약학적 조성물 및 이의 용도 |
AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
MX2017003247A (es) | 2014-09-15 | 2017-11-30 | Amgen Inc | Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas. |
CA2963091A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二重特異性抗体及び眼科に使用する方法 |
CA2963723A1 (en) * | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-pdgf-b antibodies and methods of use |
ES2764111T3 (es) | 2014-12-03 | 2020-06-02 | Hoffmann La Roche | Anticuerpos multiespecíficos |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
AU2016224583B2 (en) | 2015-02-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
KR20170122809A (ko) | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
WO2016176427A1 (en) | 2015-04-30 | 2016-11-03 | Amgen Inc. | Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
ES2828694T3 (es) * | 2015-07-29 | 2021-05-27 | Allergan Inc | Anticuerpos sólo de cadena pesada frente a ANG-2 |
WO2017023780A1 (en) | 2015-07-31 | 2017-02-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-drug conjugates for targeting cd56-positive tumors |
CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
MA42843A (fr) | 2015-09-16 | 2018-07-25 | Ablexis Llc | Anticorps anti-cd115 |
MX2018003542A (es) | 2015-09-23 | 2018-11-09 | Aerpio Therapeutics Inc | Metodos para tratar presion intraocular con activadores de tie-2. |
EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
JP6987068B2 (ja) * | 2015-11-09 | 2021-12-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 癌マーカーおよび治療標的としてのグリピカン2 |
EA201891164A1 (ru) | 2015-12-16 | 2018-11-30 | Ридженерон Фармасьютикалз, Инк. | Композиции и способы получения белковых микрочастиц |
CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
US10053515B2 (en) * | 2016-01-22 | 2018-08-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor XI antibodies |
SG10201913248VA (en) | 2016-04-18 | 2020-02-27 | Celldex Therapeutics Inc | Agonistic antibodies that bind human cd40 and uses thereof |
ES2823124T3 (es) * | 2016-06-17 | 2021-05-06 | Hoffmann La Roche | Angiopoyetina-2 (Ang-2) circulante para la predicción de recidiva de fibrilación auricular |
WO2018013939A1 (en) * | 2016-07-14 | 2018-01-18 | Scholar Rock, Inc. | Tgfb antibodies, methods, and uses |
WO2018017964A2 (en) * | 2016-07-21 | 2018-01-25 | Emory University | Ebola virus antibodies and binding agents derived therefrom |
EP3504237A1 (en) | 2016-08-23 | 2019-07-03 | Medimmune Limited | Anti-vegf-a and anti-ang2 antibodies and uses thereof |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
CN106866824B (zh) * | 2017-03-06 | 2020-10-27 | 哈尔滨医科大学 | 一种抗ddx5的全人源单克隆抗体及其制备方法和应用 |
CN109022415B (zh) * | 2017-06-12 | 2023-09-15 | 上海睿智化学研究有限公司 | PDGFRβ单克隆重链抗体杂交瘤细胞及其制备方法和应用 |
WO2019028427A1 (en) * | 2017-08-03 | 2019-02-07 | Asclepix Therapeutics, Llc. | METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR |
AU2018347521A1 (en) | 2017-10-12 | 2020-05-07 | Immunowake Inc. | VEGFR-antibody light chain fusion protein |
WO2019084307A1 (en) * | 2017-10-26 | 2019-05-02 | Celldex Therapeutics, Inc. | ANTI-MERTK ANTIBODIES AND METHODS OF USE |
EP3746470A1 (en) * | 2018-01-31 | 2020-12-09 | F. Hoffmann-La Roche AG | Stabilized immunoglobulin domains |
KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
AU2019245285A1 (en) * | 2018-03-30 | 2020-11-12 | Eureka Therapeutics, Inc. | Constructs targeting CD22 and uses thereof |
EA202092335A1 (ru) | 2018-04-02 | 2021-01-22 | Эмджен Инк. | Композиции на основе эренумаба и пути их применения |
AU2019380320A1 (en) * | 2018-11-16 | 2021-06-03 | Eureka Therapeutics, Inc. | Antibodies to Mucin-16 and methods of use thereof |
CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
JP7177284B2 (ja) * | 2019-02-25 | 2022-11-22 | ファームアブシン・インコーポレイテッド | 抗ang2抗体及びその用途 |
CN114269341A (zh) | 2019-04-29 | 2022-04-01 | 视点制药公司 | 靶向施莱姆管的Tie-2激活剂 |
WO2020227447A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors targeting glypican-2 |
CN112062849B (zh) * | 2019-06-10 | 2022-07-22 | 山东博安生物技术股份有限公司 | Cd47拮抗剂及其用途 |
JP2022539527A (ja) | 2019-06-26 | 2022-09-12 | エーピー バイオサイエンシーズ, インコーポレイテッド | T細胞活性化のための抗体 |
TW202115112A (zh) * | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
EP4183802A1 (en) * | 2020-06-22 | 2023-05-24 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-ang-2 antibody and use thereof |
US20230303711A1 (en) * | 2020-07-31 | 2023-09-28 | Bio-Thera Solutions, Ltd. | Anti-cd47 antibody and use thereof |
CN114736291B (zh) * | 2021-01-07 | 2023-08-11 | 中国科学院微生物研究所 | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 |
WO2022226539A1 (en) * | 2021-04-23 | 2022-10-27 | Immunome, Inc. | Methods of administering antibodies against sars-cov-2 spike protein |
WO2023192990A2 (en) * | 2022-03-31 | 2023-10-05 | The Wistar Institute Of Anatomy And Biology | Antibodies against human siglec-9 and use thereof for immunotherapy |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1A1 (ru) | 1921-03-25 | 1924-09-15 | А.М. Настюков | Печь дл непрерывного получени сернистого натри |
US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
ATE59966T1 (de) | 1983-09-26 | 1991-02-15 | Ehrenfeld Udo | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
CA2135313A1 (en) | 1992-06-18 | 1994-01-06 | Theodore Choi | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US5650490A (en) | 1994-10-07 | 1997-07-22 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 2 |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
EP0821728B1 (en) | 1995-04-06 | 2004-08-11 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligands, methods of making and uses thereof |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
DE19525542A1 (de) | 1995-07-13 | 1997-01-16 | Mann & Hummel Filter | Heizeinrichtung |
EP1916300A1 (en) | 1995-08-29 | 2008-04-30 | Kirin Pharma Kabushiki Kaisha | Chimeric animal and method for producing the same |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CZ291386B6 (cs) | 1996-02-13 | 2003-02-12 | Zeneca Limited | Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
US5851797A (en) | 1996-06-19 | 1998-12-22 | Regeneron Pharmaceuticals, Inc. | Tie ligand-3, methods of making and uses thereof |
US6265564B1 (en) | 1996-08-02 | 2001-07-24 | Regeneron Pharmaceuticals, Inc. | Expressed ligand-vascular intercellular signalling molecule |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
BR9912053A (pt) | 1998-07-13 | 2001-04-03 | Univ Texas | Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios |
WO2000002584A2 (en) | 1998-07-13 | 2000-01-20 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
IL145504A0 (en) | 1999-03-26 | 2002-06-30 | Regeneron Pharma | Modulation of vascular permeability by means of tie2 receptor activators |
US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
CN101073668A (zh) | 1999-04-28 | 2007-11-21 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
US6413932B1 (en) * | 1999-06-07 | 2002-07-02 | Immunex Corporation | Tek antagonists comprising soluble tek extracellular binding domain |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
EP1130094A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Primers for synthesizing full length cDNA clones and their use |
EP1206534A1 (en) | 1999-08-19 | 2002-05-22 | Genset | Prostate cancer-related gene 3 (pg3) and biallelic markers thereof |
NZ518028A (en) | 1999-11-05 | 2004-03-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
US20010055596A1 (en) | 2000-03-24 | 2001-12-27 | Meagher Madeleine Joy | Compositions and methods for therapy and diagnosis of colon cancer |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
EP1301498A1 (en) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
US7642278B2 (en) | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7205275B2 (en) * | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AU2002353017A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Discovery of therapeutic products |
US7485297B2 (en) | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
DE102004062018B4 (de) | 2004-12-23 | 2018-10-11 | Robert Bosch Gmbh | Verfahren zum Betreiben einer Brennkraftmaschine |
CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
JP4616237B2 (ja) | 2006-11-07 | 2011-01-19 | 日本電信電話株式会社 | シリコン化合物薄膜の形成方法 |
EP2642721B1 (en) | 2008-01-28 | 2015-03-11 | BlackBerry Limited | Providing session initiation protocol request contents |
AU2009209251B8 (en) * | 2008-01-28 | 2015-03-26 | Medimmune Limited | Stabilized Angiopoietin-2 antibodies and uses thereof |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2005
- 2005-12-19 ES ES05854387T patent/ES2371083T3/es active Active
- 2005-12-19 EP EP05854387A patent/EP1838733B1/en not_active Revoked
- 2005-12-19 RU RU2007127842A patent/RU2394839C2/ru active
- 2005-12-19 EP EP10185152A patent/EP2284194A1/en not_active Withdrawn
- 2005-12-19 US US11/311,939 patent/US7973140B2/en active Active
- 2005-12-19 CN CN200580048270.9A patent/CN101128483B/zh active Active
- 2005-12-19 CN CN201510208630.2A patent/CN105085678B/zh active Active
- 2005-12-19 AT AT05854387T patent/ATE521638T1/de active
- 2005-12-19 US US11/793,720 patent/US20080267971A1/en not_active Abandoned
- 2005-12-19 AU AU2005319382A patent/AU2005319382B2/en active Active
- 2005-12-19 WO PCT/US2005/045657 patent/WO2006068953A2/en active Application Filing
- 2005-12-19 SI SI200531408T patent/SI1838733T1/sl unknown
- 2005-12-19 EP EP20156190.9A patent/EP3699191A1/en active Pending
- 2005-12-19 PT PT05854387T patent/PT1838733E/pt unknown
- 2005-12-19 ZA ZA200705695A patent/ZA200705695B/xx unknown
- 2005-12-19 CA CA 2595610 patent/CA2595610C/en active Active
- 2005-12-19 DK DK05854387T patent/DK1838733T3/da active
- 2005-12-19 MX MX2007007484A patent/MX2007007484A/es active IP Right Grant
- 2005-12-19 PL PL05854387T patent/PL1838733T3/pl unknown
- 2005-12-19 BR BRPI0519596-9A patent/BRPI0519596B1/pt active IP Right Grant
- 2005-12-19 RS RSP20110477 patent/RS52036B/en unknown
- 2005-12-19 KR KR20077016981A patent/KR101017301B1/ko active IP Right Grant
- 2005-12-19 JP JP2007548333A patent/JP4884395B2/ja active Active
- 2005-12-19 NZ NZ556029A patent/NZ556029A/en not_active IP Right Cessation
- 2005-12-20 AR ARP050105364 patent/AR052065A1/es unknown
- 2005-12-21 UY UY29288A patent/UY29288A1/es not_active Application Discontinuation
- 2005-12-21 TW TW094145705A patent/TW200634027A/zh unknown
-
2007
- 2007-06-22 NO NO20073192A patent/NO20073192L/no not_active Application Discontinuation
-
2008
- 2008-03-26 HK HK08103398A patent/HK1109409A1/xx not_active IP Right Cessation
-
2011
- 2011-06-27 US US13/169,400 patent/US20120052073A1/en not_active Abandoned
- 2011-10-24 JP JP2011233284A patent/JP5642042B2/ja active Active
- 2011-11-08 CY CY20111101076T patent/CY1112909T1/el unknown
- 2011-11-18 HR HR20110859T patent/HRP20110859T1/hr unknown
-
2012
- 2012-11-30 US US13/690,120 patent/US8834880B2/en active Active
-
2014
- 2014-09-15 US US14/486,050 patent/US10066011B2/en active Active
-
2016
- 2016-05-17 HK HK16105651.1A patent/HK1217713A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112909T1 (el) | Αντισωματα που κατευθυνονται εναντια στην αγγειοποιητινη (angiopoietin)-2 και χρησεις αυτων | |
EA200602276A1 (ru) | Антитела против cd3 и способы их применения | |
CY1112876T1 (el) | Πρωτεϊνες συνδεσης ειδικες για παρομοιους με ινσουλινη παραγοντες αναπτυξης και χρησεις αυτων | |
CY1121451T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4 | |
UY29573A1 (es) | Anticuerpos dirigidos contra cd20 y sus usos | |
WO2007120693A3 (en) | Targeted binding agents directed to upar and uses thereof | |
NO20090877L (no) | Antistoffer rettet mot alfaVbeta6 og anvendelser derav | |
NO20061070L (no) | Antistoffer mot parathyoidhormon (PTH) og anvendelser derav | |
MXPA05005925A (es) | Anticuerpos dirigidos a la fosfolipasa a2 y sus usos. | |
DE60333228D1 (de) | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen | |
TW200637873A (en) | Antibodies against interleukin-1 beta | |
WO2007109307A3 (en) | Antibodies directed to angiopoietin-like protein 4 and uses thereof | |
DK1827492T3 (da) | Antistoffer rettet mod GPNMB og anvendelser deraf | |
WO2006039258A3 (en) | Human antibodies against parathyroid hormone | |
TH102395A (th) | โปรตีนจับที่จำเพาะสำหรับแฟกเตอร์เพื่อการเติบโตเช่นอินซูลินและการใช้โปรตีนจับเหล่านี้ | |
TH102395B (th) | โปรตีนจับที่จำเพาะสำหรับแฟกเตอร์เพื่อการเติบโตเช่นอินซูลินและการใช้โปรตีนจับเหล่านี้ | |
TH94700B (th) | แอนติบอดีที่มุ่งต่อ cd20 และการใช้ของมัน | |
TH94700A (th) | แอนติบอดีที่มุ่งต่อ cd20 และการใช้ของมัน |